BGPT: Paper Review: CRISPR prime editing for unconstrained correction of oncogenic KRAS variants

Explore by Goal

Quick Explanation Copied

Core claim (paper)

Using universal pegRNAs, the authors report correction of 12 oncogenic KRAS G12/G13 missense variants via CRISPR prime editing, with up to ~54.8% correction in HEK293T/17 pooled libraries and up to ~40.6% (G13D) correction in endogenous contexts, and reduced-correction over time interpreted as a growth disadvantage for KRAS-corrected populations.

Read alongside: prime editing mechanics and design logic from the original PE foundational work ( and the prime-editor design principle that editing outcome depends on nick-to-edit distance (), plus the specific engineering strategy used in this paper ().

Long Explanation

Paper Review (visual first): Universal prime editing of oncogenic KRAS G12/G13

“CRISPR prime editing for unconstrained correction of oncogenic KRAS variants”

doi: 10.1038/s42003-023-05052-1

What the authors did (operational map)

Universal pegRNA design targeting KRAS codon positions spanning G12 and G13 by using two adjacent protospacer strategies (KRAS-#1 / KRAS-#2) and a PAM-flexible PE variant (PE2-SpG) ().
Library test: establish an HEK293T/17 pooled library with 12 KRAS mutant targets and barcoding; quantify correction via PCR + targeted deep sequencing ().
Optimization: evaluate pegRNA variants (PBS/RTT lengths) and show improvements with PE3b-SpG and engineered epegRNA scaffolds (tevopreQ1, tmpknot) ().
Endogenous correction: generate HEK293T/17 clones bearing heterozygous KRAS mutations; correct using the universal pegRNA (and variants) and quantify correction by targeted deep sequencing; confirm allelic changes with Sanger sequencing ().

Data visualization (from extracted figure values)

Note: The heatmap below uses the nine universal pegRNA conditions encoded in the paper’s reported correction-frequency matrix (PBS nt: 9/11/13; RTT nt: 10/13/16) across the 12 KRAS G12/G13 missense targets, as included in your extracted dataset.

How to read the main plot (mechanistic interpretation, with skepticism)

Pattern A: Higher correction appears for some mutations under longer RTT/PBS combinations, consistent with the general PE design principle that guide geometry influences prime-editing efficiency ().

Pattern B: The “universal” strategy does not yield uniform performance: different KRAS variants reach different maxima even within the same universal pegRNA set. That implies the mapping from RTT/PBS geometry to the exact nucleotide substitution context is not merely a “yes/no” coverage claim; it is quantitative and mutation-specific ().

Main scientific claims (what seems well-supported)

Broad mutation coverage claim (G12/G13): The authors explicitly state universal pegRNAs corrected a set of 12 KRAS G12/G13 oncogenic missense variants with quantified correction frequencies in a HEK293T/17 pooled library, and they further emphasize that these account for a large fraction of known KRAS mutations in their stated scope ().
Quantification is by targeted deep sequencing: Correction frequencies are computed from targeted amplicons + deep sequencing (and barcode classification in the library). This is stronger than relying on a single readout like bulk phenotype alone ().
Endogenous contexts in multiple cell lines: They report endogenous KRAS corrections in HEK293T/17 clones and in multiple cancer cell lines (pancreatic: CFPAC-1, ASPC-1; colon: HCT116), with variant-dependent correction levels ().

Critical evaluation (skeptical blind spots & falsifiable gaps)

Off-target evaluation is limited: The paper reports targeted deep sequencing checks at five predicted off-target sites with no remarkable mutations, and notes that higher-throughput genome-wide analyses (e.g., transcriptome) might be needed to fully elucidate off-target effects ().
Editing success ≠ safety or on-target selectivity in vivo: Lack of detectable indels/substitutions at endogenous KRAS sites in the tested conditions does not establish genome-wide specificity or long-term genomic stability. Prime editing still requires comprehensive off-target and structural rearrangement assessment to support translation; the paper itself does not provide those breadth-of-evidence experiments within the presented scope ().
Cell-line context dependence: Correction efficiencies are described as lower in certain pancreatic cancer cell lines compared with HEK293T/17, which may reflect differences in delivery, chromatin accessibility, cell-state determinants of editing outcomes, or allele dosage/imbalance. This constrains generality beyond the tested lines ().
Phenotype linkage is incomplete: The paper includes observations consistent with a growth disadvantage of corrected KRAS populations (editing frequencies decrease over time in at least one context), but it is not a full functional causal demonstration that all corrected alleles drive the measured phenotype in every model ().

Epistemic humility: what would most disprove the “universal” therapeutic framing?

Variant-agnostic failure across broader panels: demonstrate that universal pegRNAs do not correct additional KRAS variants beyond the tested 12, or perform substantially worse in other genomic contexts than in the tested cell lines ().
Hidden genome-wide off-targets: find reproducible off-target edits outside the five predicted loci, including structural changes or widespread transcriptomic dysregulation, in sufficiently powered assays (the paper itself calls for broader analyses) ().
Loss of functional effect: show correction does not reduce downstream KRAS signaling or cell fitness in a way that tracks correction levels across independent models, timepoints, and delivery modalities (the paper includes frequency changes over time, but does not present a broad downstream pathway causality suite in the provided text) ().

Author reviews (BGPT links)

Optional deeper perspectives via BGPT author-review pages.

Feedback:

Updated: March 30, 2026